Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/17/15  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Gary E. Frashier

Wrong Gary E. Frashier?

Managing Partner

Targeted Technology Fund II
Phone: (210) ***-****  HQ Phone
Email: g***@***.com
Targeted Technology
18618 Tuscany Stone, Suite 100
San Antonio , Texas 78258
United States

Company Description: The Targeted Technology Funds are focused on early stage investments in companies that we believe can advance ground breaking or disruptive technologies to...   more

Employment History

Board Memberships and Affiliations


  • B.S. , Chemical Engineering
    Texas Tech University
  • M.B.A.
    Massachusetts Institute of Technology
  • B.S , Chemical Engineering
    Texas Tech University
102 Total References
Web References
Targeted Technology | Gary Frashier, 17 Aug 2015 [cached]
Gary Frashier, MBA, PE Targeted Technology | Gary Frashier Targeted Technology
Gary Frashier, MBA, PE
Gary Frashier
Managing Partner
Gary Frashier brings extensive experience to the Fund, having served as a Chief Executive Officer for over 24 years in life science and specialty chemicals, and has over 17 years of experience in international operations. Gary served as the CEO and Chairman of OSI Pharmaceuticals, Inc, and it was during his nine year tenure at OSI that the leading genetic-based cancer drug, "Tarceva", was discovered and developed through proof-of-concept human clinical trials. Tarceva is now sold globally by Roche, Genentech and Astellas for the treatment of many solid tumors with sales of over $1.9 Billion per year. OSI was acquired by Astellas in 2010 for a price of $4 Billion.
Prior to OSI, Gary served as Executive Vice President of Millipore Corporation and as President of their International Operations. When Millipore acquired Waters Corporation, he served as President and CEO of their Waters Chromatography subsidiary. Prior to this, he joined Genex Corporation, which discovered, developed and patented the first single-chain antibodies.
Gary financed over $250 Million in capital for his companies from a combination of equity fundings and other sources, and is a Strategic Partner in SV Life Sciences, a major Boston venture capital company. Gary has served as a founder of several life sciences companies, including Merrimack Pharmaceuticals, Eutropics, America Stem Cell, and Apex BioVentures Acquisition Corporation. He has also served on the Board of Directors of Maxim Pharma, Merrimack Pharma, Tekmira, Exegenics, Aderis Pharma, and Alseres Pharma, and is currently on the Boards of Achillion Pharmaceuticals, (NASDAQ:ACHN), ViroXis Corporation, StemBioSys and Metric Medical. Gary has a BS in Chemical Engineering from Texas Tech University and an MS from the Massachusetts Institute of Technology in Management (Alfred P. Sloan Fellow).
Achillion Pharmaceuticals: Board of Directors, 10 Mar 2015 [cached]
Gary E. Frashier
Mr. Frashier joined Achillion's Board of Directors in March 2008 and currently serves as Chair of the Compensation Committee and as a member of the Audit Committee.
Gary E. Frashier, age ..., 18 April 2014 [cached]
Gary E. Frashier, age 76. Mr. Frashier has served as a director of Achillion since March 2008 and currently serves as chair of our Compensation Committee and as a member of our Audit Committee. Mr. Frashier, through his company Management Associates, has been a strategic consultant to emerging growth companies in the life sciences field since 2000. From 1990 until 1998, he served as Chief Executive Officer of OSI Pharmaceuticals, Inc., a biotechnology company, and from 1997 until 2000, as its Chairman of the Board. From 1987 until 1990, he served as President and CEO of Genex Corporation, a protein engineering company, and from 1984 until 1987, as Chairman and CEO of Continental Water Systems, Inc., a manufacturer and marketer of equipment to produce high purity water used by the pharmaceutical, medical, electronics and research industries. Mr. Frashier also served as Executive Vice President of Millipore Corporation, a provider of products and services to biopharmaceutical, manufacturing, clinical, analytical and research laboratories, and as President of Millipore’s Waters Associates subsidiary. Mr. Frashier also serves on the Board of Directors of privately held Metric Medical Devices, a medical device company, StemBioSys, a stem cell technology company and Viroxis Corporation, a biopharmaceutical company. Mr. Frashier received a B.S. in Chemical Engineering from Texas Tech University and received his M.B.A. from the Massachusetts Institute of Technology, where he was a Sloan Fellow. Mr. Frashier’s qualifications include extensive managerial, manufacturing and merger and acquisition experience as a chief executive officer of multiple life sciences industry companies. As a director with several emerging technology companies, and as a consultant in the industry, Mr. Frashier also provides extensive experience in compensation management, alliance management and strategy development, all of which enhances his value on our Board.
ViroXis - Management & Partners, 21 Mar 2015 [cached]
Gary E. Frashier
Mr. Frashier is President and Principal of Management Associates, and brings extensive experience in Life science management, operations and transactions having served as a CEO for twenty four years, mostly in this area.
America Stem Cell, 4 Feb 2012 [cached]
Gary Frashier, M.B.A Executive Chairman of the Board & Co-Program/Project Team Leader for the ASC 101 Development Program
Gary is the President and Principal of Management Associates and brings extensive experience in life science company transactions and commercial operations. Prior to founding Management Associates in 1999, Mr. Frashier served as President and Chief Executive Officer of OSI Pharmaceuticals, a drug discovery company, from 1990 through 1998, and also as its Chairman of the Board from 1997 to 2000. During his tenure at OSI, the leading cancer drug "Tarceva" was discovered by OSI and it is now sold together with Genentech and Roche. Gary was instrumental in establishing strategic alliances with Pfizer, Hoechst, Sankyo, Roche and American Home Products and raised over $150 million from a combination of equity financings, grant awards, milestone payments and up-front fees.
Other People with the name "Frashier":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.